About
Martin Lauss is an Associate Researcher and Melanoma Genomics Researcher at the Lund University Cancer Centre (LUCC) at Lund University. As a bioinformatician in the Melanoma Genomics Group, he specializes in cancer genomics and biomedical statistics with particular expertise in gene expression analysis, copy number analysis, DNA methylation arrays, and next generation sequencing.
His research focuses on understanding melanoma through genomic analysis, demonstrating that melanoma tumors can be grouped based on similarities in gene expression levels of the MITF gene, as well as proliferation, immune, and stroma genes. These molecular subtypes represent fundamental biological entities of melanoma with differing patient outcomes, and Dr. Lauss hypothesizes that therapy response and resistance are also determined by these groups.
Dr. Lauss's research fingerprint shows significant contributions to Nodular Melanoma (100%), Gene research (95%), Patient studies (54%), Microphthalmia-Associated Transcription Factor (38%), Survival analysis (35%), T Cell immunology (31%), Gene Expression Profiling (28%), and Epigenetics (25%). His work contributes to UN Sustainable Development Goals related to health and well-being.
His recent publications in high-impact journals like Nature and Nature Communications explore critical topics including immune checkpoint blockade resistance, DNA promoter hypermethylation in melanoma, and the complex relationship between immune cells and tumor microenvironments.
Martin Lauss has been actively involved in academic community building, having participated in organizing the LUCC - Skin retreat conference (2024-2025) and the LUCC - Skin: Retreat conference (2022) where he served as a presenter. His research collaborations span multiple institutions and countries, reflecting the international nature of cancer research.
